In June 2015, when officials of Matinas Biopharma Holdings Inc. saw the results of the 42-patient trial testing its omega-3 fatty acid-based MAT-9001 for high triglycerides against the approved Vascepa (icosapent ethyl) from Dublin-based Amarin Corp. plc, they knew they had something. But, at the time, "there was not a lot of wind in the sails" of cardiovascular (CV) research, Matinas CEO Jerome Jabbour told BioWorld. "Everyone knew it would be another three years before Amarin was ready to talk about its outcomes study."